Dyadic International partners with Rabian BV to develop affordable rabies prophylactics using its C1 protein production platform. The collaboration aims to address global rabies burden, receiving Eurostars funding for the AVATAR project. Dyadic gains equity, funding, and royalties, leveraging expertise to combat rabies in lower- and middle-income countries, emphasizing preventive vaccination’s crucial role in saving lives and reducing transmission.
Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a leading global biotechnology firm dedicated to leveraging its cutting-edge microbial protein production platforms, has announced a strategic partnership agreement with Rabian BV (“Rabian”), a Dutch innovative SME specializing in vaccine development. This collaboration aims to harness Dyadic’s proprietary C1 protein production platform to create cost-effective and efficient rabies prophylactics and vaccines, addressing the pressing global need for accessible biopharmaceutical solutions for both human and animal health.
Through its Dutch subsidiary, Dyadic Nederland BV, Dyadic will join forces with Rabian to develop highly effective and scalable rabies prophylactics and vaccines. This initiative targets the significant burden of rabies, a disease that annually claims numerous lives worldwide.
The partnership, awarded by Eurostars for the AVATAR project, will receive approximately €1.7 million in total funding, including co-funding from the European Union through Horizon Europe. Rabian will leverage its expertise in virology to lead the development of a rabies vaccine using Dyadic’s C1 protein production platform, particularly focusing on addressing the challenges posed by rabies in lower- and middle-income countries (LMICs).
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Under the terms of the strategic partnership agreement, Dyadic will receive an equity stake in Rabian, full funding for research and development costs, and specified royalties upon commercialization, further solidifying its commitment to advancing global health initiatives.
Mark Emalfarb, CEO of Dyadic, expressed enthusiasm for the collaboration, emphasizing the potential to provide affordable vaccines and prophylactics for LMICs while exploring opportunities for human health commercial products using Dyadic’s C1 platform. Emalfarb highlighted the urgent need to combat rabies, a disease responsible for thousands of deaths annually, and praised Rabian’s expertise as a valuable asset in addressing this critical health issue.
Drs. Carine Punt, CEO of Rabian, underscored the long-standing collaboration between Rabian and Dyadic, spanning nearly a decade and encompassing projects such as the EU-funded Zoonosis Anticipation Preparedness Initiative (ZAPI) and pre-clinical vaccine development for diseases like rabies and COVID-19. Drs. Punt emphasized the potential of integrating advances in vaccinology with Dyadic’s C1 platform to accelerate research, streamline product development, and reduce manufacturing costs.
Highlighting the ongoing threat of rabies to human lives, particularly in resource-limited communities, Drs. Punt stressed the importance of expanding access to preventive vaccination, especially for travelers visiting endemic areas. Despite the availability of preventive measures and post-exposure treatment, rabies continues to pose a significant public health challenge, with the highest incidence observed in LMICs. Drs. Punt urged concerted efforts to combat rabies and ensure widespread prevention through accessible and cost-effective vaccination strategies.